Spark Roche Merger Agreement

Terms of The Agreement Pursuant to the terms of the Merger Agreement, Roche will immediately make an offer to purchase all of the outstanding common shares of Spark Therapeutics at a price of $114.50 per share in cash. The completion of the takeover bid is subject to the condition that the majority of the outstanding shares be paid by Spark Therapeutics. In addition, the transaction is subject to the condition of expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Upon completion of the takeover bid, Roche will acquire all remaining shares at the same price of $US 114.50 per share in a subsequent merger. The transaction is expected to close in the second quarter of 2019. Centerview Partners is financial advisor to Spark Therapeutics and Goodwin Procter LLP is legal advisor to Spark Therapeutics. Cowen also acted as financial advisor in this transaction for Spark Therapeutics. Citi is financial advisor to Roche and Davis Polk & Wardwell LLP as legal advisor to Roche. About Spark Therapeutics At Spark Therapeutics, a fully integrated commercial enterprise dedicated to the discovery, development and delivery of gene therapies, we question the ineligibility of genetic diseases, including blindness, hemophilia, lysosomal memory disorders and neurodegenerative diseases. We have successfully used our technology in the first gene therapy, licensed for a genetic disease in the US and EU, and we currently have four programs in clinical trials, including product candidates, that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where life is not limited by genetic diseases. For more information, visit www.sparktx.com and follow us on Twitter and LinkedIn. Spark Therapeutics` merger with Roche came closer after the UK competition authority approved the $4.8 billion deal before a regulatory deadline in the US expired.

Initiation of a merger investigation and publication of the initiation notice. About Spark Therapeutics At Spark Therapeutics, a fully integrated commercial enterprise dedicated to the discovery, development and delivery of gene therapies, we question the ineligibility of genetic diseases, including blindness, hemophilia, lysosomal memory disorders and neurodegenerative diseases. We have successfully used our technology in the first gene therapy licensed in the US and EU for a genetic disease, and we currently have four clinical trial programs, including product candidates, that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where life is not limited by genetic diseases. For more information, visit www.sparktx.com and follow us on Twitter and LinkedIn. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) announced today that they have entered into a definitive merger agreement for Roche for the complete acquisition of Spark Therapeutics at a price of US$114.50 per share in a cash transaction. . . .